ARTICLE | Deals
Novartis and Ionis aim for best in class with latest Lp(a) deal
As new entrants join Lp(a) competition, Novartis and Ionis are looking beyond the first-mover advantage of Phase III candidate pelacarsen
August 3, 2023 10:30 PM UTC
As Novartis and Ionis await Phase III data from potential first-in-class Lp(a) inhibitor pelacarsen, the partners anticipate the need for a follow-on product to achieve best-in-class status.
On Tuesday, Novartis AG (SIX:NOVN; NYSE:NVS) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) announced they struck a new deal to create a next-generation antisense oligonucleotide therapy against Lp(a) that they hope “will provide industry-leading efficacy and dosing frequency.”...